Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2022-12-15 Earnings Release
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
bioMérieux – Relèvement des perspectives 2022 et version préliminaire des perspectives 2023
Earnings Release Classification · 100% confidence The document is a press release dated December 15, 2022, titled "bioMérieux – Relèvement des perspectives 2022 et version préliminaire des perspectives 2023" (bioMérieux – Raising 2022 outlook and preliminary 2023 outlook). It provides updated financial guidance for the full year 2022 and preliminary guidance for 2023, specifically mentioning revenue growth and operating income targets. This content aligns perfectly with an Earnings Release (ER), which is defined as the initial announcement of periodical financial results (key highlights only). Although it discusses future outlook, the core function is reporting preliminary/updated financial performance expectations, which is characteristic of an ER, rather than a comprehensive report (10-K or IR) or a management discussion (MDA). It is not a report publication announcement (RPA) because it contains the actual preliminary results/guidance, not just an announcement that a report is coming. The next full results are scheduled for March 8, 2023, confirming this is an interim/preliminary update. FY 2022
2022-12-15 French
Novembre 2022 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as required by French commercial code and AMF regulations. This type of filing, which reports on share capital structure and voting rights, is best categorized under general regulatory filings or specific share/capital change notifications. Given the options, it is a specific regulatory disclosure about share capital structure, but it doesn't fit perfectly into SHA (Share Issue/Capital Change) as it's a periodic disclosure of existing rights, nor DVA (Declaration of Voting Results) which is for meeting outcomes. Since it is a mandatory regulatory disclosure concerning share structure and voting rights, and it is not a full financial report or an earnings release, the most appropriate general category for mandatory, non-standardized regulatory updates is RNS (Regulatory Filings). However, the content is highly specific to share capital structure reporting. If we strictly follow the definitions, it is a regulatory filing about share structure. Let's re-evaluate the options. It is not a dividend notice (DIV), not a director dealing (DIRS), and not a major shareholding notification (MRQ) which usually relates to crossing thresholds. It is a mandatory monthly report on the total number of shares and voting rights. This is a common type of filing in European markets. Given the available codes, RNS (Regulatory Filings) serves as the best fit for mandatory, periodic regulatory disclosures that don't match other specific categories like 10-K, ER, or IR. The document is short and is a direct regulatory disclosure, not an announcement of another report.
2022-12-05 French
Octobre 2022 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share capital structure and voting rights, is most closely aligned with the general category of regulatory announcements or specific capital structure updates. Given the options, it is a specific regulatory disclosure about share capital and voting rights. While it relates to capital, it is a mandatory periodic disclosure rather than a financing event (CAP) or a share repurchase (POS). It fits best under the general 'Regulatory Filings' (RNS) as a specific, recurring regulatory disclosure that doesn't match the other specialized codes like DIRS or MRQ, although it is highly specific. However, since it details the 'Nombre total de droits de vote' and 'Nombre d'actions' as of a specific date (31/10/2022), it is a direct report on share capital structure, which is often grouped with other capital/share notifications. Given the strict definitions, RNS is the most appropriate fallback for mandatory regulatory disclosures not covered elsewhere. It is not a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ).
2022-11-07 French
bioMérieux – Third-Quarter 2022 Business Review
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Third-Quarter 2022 Business Review" and explicitly states it "releases its business review for the nine months ended September 30, 2022." It contains detailed financial tables comparing Q3 2022/9M 2022 results against prior periods, analysis by application and region, and management commentary on performance. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year (nine months). Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/ER) because it contains extensive financial detail, nor is it the Annual Report (10-K). 9M 2022
2022-10-26 English
bioMérieux – Information financière du 3ème trimestre 2022
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Information financière du 3 ème trimestre 2022" and provides detailed financial figures, revenue breakdowns by application and region, and commentary for the first nine months (9 mois) and the third quarter (T3) ending September 30, 2022. This structure—a comprehensive report covering a period shorter than a full year—is characteristic of an Interim/Quarterly Report. The date of communication is October 26, 2022, which aligns with reporting quarterly results. This fits the definition of an Interim / Quarterly Report (IR) much better than a brief Earnings Release (ER) or a full Annual Report (10-K). 9M 2022
2022-10-26 French
Septembre 2022 - Déclaration relative au nombre d'actions composant le capital social et le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share capital structure and voting rights, is not explicitly covered by the primary definitions (like 10-K, ER, or DIV). However, it is a specific regulatory disclosure related to share capital and ownership structure. Given the options, it is closest to a general regulatory filing or a specific capital/share announcement. Since it details the total number of shares and voting rights as of a specific date (30/09/2022), it relates to the company's capital structure. It is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Share Issue/Capital Change (SHA) which usually focus on transactions or changes. It is a mandatory periodic disclosure. In the absence of a specific 'Voting Rights Disclosure' code, the most appropriate general regulatory category is RNS, or potentially SHA if interpreted broadly as capital structure information. Given the focus on 'droits de vote et d'actions' (voting rights and shares) as a mandatory monthly report, RNS (Regulatory Filings) serves as the best fit for this specific, recurring regulatory disclosure that doesn't match the other specific codes perfectly.
2022-10-04 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.